Vical completes phase one trial of H1N1 vaccine

Vical Incorporated announced on Wednesday that half of the subjects in a phase 1 trial of its formulated vaccine for H1N1 pandemic influenza generated neutralizing antibodies that are expected to provide protection against the disease.

The vaccine, Vaxfectin, was well-tolerated and demonstrated the safety and immunogenicity of the same vaccine used in animals studies prior to the phase 1 human trial, reports.  

The CDC estimated that between 14 million and 34 million cases of 2009 H1N1 cases and related hospitalizations and deaths occurred in the United States between April and October 17, 2009, a period when the virus was most rampant.  

Vical was the first company to manufacture a vaccine against the H1N1 virus in 2009. The trial was supported by U.S. government funding from the Defense Threat Reduction Agency and the U.S. Naval Medical Research Center.

“We clearly demonstrated the speed and safety of our approach during the 2009 H1N1 pandemic influenza outbreaks,” Larry R. Smith, Vical’s vice president of vaccine research, said, according to

Based in San Diego, California, Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.